Celyad Oncology Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Matt Kane
Chief executive officer
€179.7k
Total compensation
| CEO salary percentage | 56.7% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.8yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €180k | €102k | -€6m |
Compensation vs Market: Matt's total compensation ($USD202.27K) is below average for companies of similar size in the German market ($USD496.77K).
Compensation vs Earnings: Insufficient data to compare Matt's compensation with company performance.
CEO
Matt Kane (48 yo)
less than a year
Tenure
€179,740
Compensation
Mr. Matthew R. Kane, also known as Matt, is Chief Executive Officer of Celyad Oncology SA since October 1, 2024 and its Executive Director since December 2024. Mr. Kane was the Chief Executive Officer and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | less than a year | €179.74k | no data | |
| Co-Founder & Non-Executive Director | no data | €109.24k | 0.38% € 72.0k | |
| Vice President of Finance & Administration | 2.8yrs | no data | no data | |
| Communications & Investor Relations Director | no data | no data | no data | |
| Head of Legal | 2.8yrs | no data | no data | |
| Head of Intellectual Property | 2.8yrs | no data | no data | |
| Head of R&D | 2.9yrs | no data | no data | |
| Corporate Secretary | no data | no data | no data |
2.8yrs
Average Tenure
48yo
Average Age
Experienced Management: 1C0's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | less than a year | €179.74k | no data | |
| Co-Founder & Non-Executive Director | 18.3yrs | €109.24k | 0.38% € 72.0k | |
| Independent Chairwoman of the Board | 8.3yrs | €40.64k | no data | |
| Non-Executive Director | 17.3yrs | €644.00 | 0.14% € 25.8k | |
| Member of Scientific Advisory Board | no data | €10.00k | no data | |
| Member of Scientific Advisory Board | 9.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.1yrs | no data | no data | |
| Independent Director | 5yrs | €40.00k | no data | |
| Independent Director | 5yrs | €40.00k | no data | |
| Non-Executive Director | 3.4yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 3.3yrs | no data | no data |
6.7yrs
Average Tenure
62.5yo
Average Age
Experienced Board: 1C0's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 19:22 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celyad Oncology SA is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| John Savin | Edison Investment Research |
| Edward White | H.C. Wainwright & Co. |